Captor Therapeutics S.A. (CTX) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.346x

Based on the latest financial reports, Captor Therapeutics S.A. (CTX) has a cash flow conversion efficiency ratio of -0.346x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.51 Million ≈ $-3.17 Million USD) by net assets (zł33.27 Million ≈ $9.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Captor Therapeutics S.A. (CTX) balance sheet quality index to measure how much of total assets are equity-financed.

Captor Therapeutics S.A. - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Captor Therapeutics S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Captor Therapeutics S.A. cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Captor Therapeutics S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Captor Therapeutics S.A. ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Brouwerij Handelsmaatschappij NV BR:COBH	0.120x
flyExclusive, Inc. NYSE MKT:FLYX	0.009x
Aeternal Mentis SA MC:AMEN	-0.051x
Reward Wool Industry Corp TW:1423	0.004x
Rent the Runway Inc NASDAQ:RENT	0.071x
Impact Develop RO:IMP	-0.002x
Global Fashion Group SA XETRA:GFG	0.048x
CJ CheilJedang Corp KO:097955	0.068x

Annual Cash Flow Conversion Efficiency for Captor Therapeutics S.A. (2017–2024)

The table below shows the annual cash flow conversion efficiency of Captor Therapeutics S.A. from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Captor Therapeutics S.A..

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	zł64.47 Million ≈ $17.74 Million	zł-31.88 Million ≈ $-8.77 Million	-0.494x	+34.44%
2023-12-31	zł69.22 Million ≈ $19.05 Million	zł-52.20 Million ≈ $-14.37 Million	-0.754x	-216.56%
2022-12-31	zł96.32 Million ≈ $26.51 Million	zł-22.95 Million ≈ $-6.32 Million	-0.238x	-3.92%
2021-12-31	zł124.20 Million ≈ $34.18 Million	zł-28.47 Million ≈ $-7.84 Million	-0.229x	-138.68%
2020-12-31	zł-1.00 Million ≈ $-276.32K	zł-595.00K ≈ $-163.75K	0.593x	-42.31%
2019-12-31	zł4.28 Million ≈ $1.18 Million	zł4.39 Million ≈ $1.21 Million	1.027x	+265.41%
2018-12-31	zł3.43 Million ≈ $944.26K	zł-2.13 Million ≈ $-586.48K	-0.621x	-104.27%
2017-12-31	zł144.00K ≈ $39.63K	zł2.10 Million ≈ $577.12K	14.563x	--

About Captor Therapeutics S.A.

WAR:CTX Poland Biotechnology

Market Cap

$112.49 Million

zł408.75 Million PLN

Market Cap Rank

#18694 Global

#143 in Poland

Share Price

zł74.20

Change (1 day)

+0.00%

52-Week Range

zł34.60 - zł87.60

All Time High

zł202.00